{"cluster": 62, "subcluster": 7, "abstract_summ": "Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection.Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.A quick way to test compounds with potential antiviral activity is through drug repurposing.In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future.Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.", "title_summ": "Targeting SARS-CoV-2: Novel Source of Antiviral Compound(s) against COVID-19?Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivoPotential antiviral options against SARS-CoV-2 infectionIdentification of potent and safe antiviral therapeutic candidates against SARS-CoV-2Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugsCandidate drugs against SARS-CoV-2 and COVID-19Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In VitroOral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19Potential Antiviral Options against SARS-CoV-2 Infection.", "title_abstract_phrases": "Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection.Overall, our results emphasize the importance of both drug repurposing and preclinical testing of drug combinations for potential therapeutic use against SARS-CoV-2 infections.In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.Candidate drugs against SARS-CoV-2 and COVID-19Outbreak and pandemic of coronavirus SARS-CoV-2 in 2019/2020 will challenge global health for the future.Further, chloroquine and hydroxychloroquine, and off-label antiviral drugs, such as the nucleotide analogue remdesivir, HIV protease inhibitors lopinavir and ritonavir, broad-spectrum antiviral drugs arbidol and favipiravir as well as antiviral phytochemicals available to date may prevent spread of SARS-CoV-2 and morbidity and mortality of COVID-19 pandemic.A quick way to test compounds with potential antiviral activity is through drug repurposing."}